 10. Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or has not recovered i.e. Grade 1 or at baseline from adverse events due to previously administered event. Note: Subjects with Grade 2 neuropathy are an exception to this criterion and may qualify for this study. If subject received major surgery, they must have recovered adequately from the toxicity andor complications from the intervention prior to starting therapy. 